Second-Line Treatment of Pancreatic Adenocarcinoma: Shedding Light on New Opportunities and Key Talking Points from Clinical Trials

References

• Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin. 2023;73(1):17–48. doi:10.3322/caac.21763
   PubMed Web of Science ®Google Scholar
• SEER Cancer Stat Facts. Cancer Stat Facts: pancreatic Cancer; 2023. Available from: https://seer.cancer.gov/statfacts/html/pancreas.html. Accessed July 9, 2023.
   Google Scholar
• Ullman NA, Burchard PR, Dunne RF, Linehan DC. Immunologic strategies in pancreatic cancer: making cold tumors hot. J Clin Oncol. 2022;40(24):2789–2805. doi:10.1200/JCO.21.02616
   PubMed Web of Science ®Google Scholar
• Nakazawa H, Yoshihara S, Kudo D, et al. 4-methylumbelliferone, a hyaluronan synthase suppressor, enhances the anticancer activity of gemcitabine in human pancreatic cancer cells. Cancer Chemother Pharmacol. 2006;57(2):165–170. doi:10.1007/s00280-005-0016-5
   PubMedGoogle Scholar
• Wang Y, Li XL, Mo YZ, et al. Effects of tumor metabolic microenvironment on regulatory T cells. Mol Cancer. 2018;17(1). doi:10.1186/s12943-018-0913-y
   Google Scholar
• Rahma OE, Katz MHG, Wolpin BM, et al. Randomized multicenter phase Ib/II study of neoadjuvant chemoradiation therapy (CRT) alone or in combination with pembrolizumab in patients with resectable or borderline resectable pancreatic cancer. J Clin Oncol. 2021;39(15_suppl):4128. doi:10.1200/JCO.2021.39.15_suppl.4128
   Web of Science ®Google Scholar
• Gaudreau PO, Negrao MV, Mitchell KG, et al. Neoadjuvant chemotherapy increases cytotoxic T cell, tissue resident memory T cell, and B cell infiltration in resectable NSCLC. J Thorac Oncol. 2021;16(1):127–139. doi:10.1016/j.jtho.2020.09.027
   PubMed Web of Science ®Google Scholar
• Pelekanou V, Carvajal-Hausdorf DE, Altan M, et al. Effect of neoadjuvant chemotherapy on tumor-infiltrating lymphocytes and PD-L1 expression in breast cancer and its clinical significance. Breast Cancer Res. 2017;19(1):91. doi:10.1186/s13058-017-0884-8
   PubMed Web of Science ®Google Scholar
• Xing X, Shi J, Jia Y, et al. Effect of neoadjuvant chemotherapy on the immune microenvironment in gastric cancer as determined by multiplex immunofluorescence and T cell receptor repertoire analysis. J Immunother Cancer. 2022;10(3):e003984. doi:10.1136/jitc-2021-003984
   PubMed Web of Science ®Google Scholar
• Lim SH, Chua W, Cheng C, et al. Effect of neoadjuvant chemoradiation on tumor-infiltrating/associated lymphocytes in locally advanced rectal cancers. Anticancer Res. 2014;34(11):6505–6513.
   PubMed Web of Science ®Google Scholar
• Balachandran VP, Łuksza M, Zhao JN, et al. Identification of unique neoantigen qualities in long-term survivors of pancreatic cancer. Nature. 2017;551(7681):512–516. doi:10.1038/nature24462
   PubMed Web of Science ®Google Scholar
• Kamisawa T, Wood LD, Itoi T, Takaori K. Pancreatic cancer. Lancet. 2016;388(10039):73–85. doi:10.1016/S0140-6736(16)00141-0
   PubMed Web of Science ®Google Scholar
• Liu J, Ji S, Liang C, et al. Critical role of oncogenic KRAS in pancreatic cancer (Review). Mol Med Rep. 2016;13(6):4943–4949. doi:10.3892/mmr.2016.5196
   PubMed Web of Science ®Google Scholar
• Ischenko I, D’Amico S, Rao M, et al. KRAS drives immune evasion in a genetic model of pancreatic cancer. Nat Commun. 2021;12(1):1482. doi:10.1038/s41467-021-21736-w
   PubMed Web of Science ®Google Scholar
• de Leve S, Wirsdörfer F, Jendrossek V. Targeting the immunomodulatory CD73/Adenosine system to improve the therapeutic gain of radiotherapy. Front Immunol. 2019;10:698. doi:10.3389/fimmu.2019.00698
   PubMed Web of Science ®Google Scholar
• Zhang Z, Rohweder PJ, Ongpipattanakul C, et al. A covalent inhibitor of K-Ras(G12C) induces MHC class I presentation of haptenated peptide neoepitopes targetable by immunotherapy. Cancer Cell. 2022;40(9):1060–1069.e7. doi:10.1016/j.ccell.2022.07.005
   PubMed Web of Science ®Google Scholar
• Hu H, Cheng R, Wang Y, et al. Oncogenic KRAS signaling drives evasion of innate immune surveillance in lung adenocarcinoma by activating CD47. J Clin Invest. 2023;133(2). doi:10.1172/JCI153470
   Web of Science ®Google Scholar
• Luo J. KRAS mutation in pancreatic cancer. Semin Oncol. 2021;48(1):10–18. doi:10.1053/j.seminoncol.2021.02.003
   PubMed Web of Science ®Google Scholar
• Yousef A, Yousef M, Chowdhury S, et al. Impact of KRAS mutations and co-mutations on clinical outcomes in pancreatic ductal adenocarcinoma. NPJ Precis Oncol. 2024;8(1):27. doi:10.1038/s41698-024-00505-0
   PubMed Web of Science ®Google Scholar
• Ardalan B, Ciner A, Baca Y, et al. Not all treated KRAS- mutant pancreatic adenocarcinomas are equal: KRAS G12D and survival outcome. J Clin Oncol. 2023;41(16_suppl):4020. doi:10.1200/JCO.2023.41.16_suppl.4020
   Google Scholar
• Luchini C, Paolino G, Mattiolo P, et al. KRAS wild-type pancreatic ductal adenocarcinoma: molecular pathology and therapeutic opportunities. J Exp Clin Cancer Res. 2020;39(1):227. doi:10.1186/s13046-020-01732-6
   PubMed Web of Science ®Google Scholar
• National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Pancreatic adenocarcinoma V.2.2023. Available from: https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1455. Accessed September 13, 2023.
   Google Scholar
• Wang-Gillam A, Hubner RA, Siveke JT, et al. NAPOLI-1 Phase 3 study of liposomal irinotecan in metastatic pancreatic cancer: final overall survival analysis and characteristics of long-term survivors. Eur J Cancer. 2019;108:78–87. doi:10.1016/j.ejca.2018.12.007
   PubMed Web of Science ®Google Scholar
• Weinberg BA, Wang H, Pedersen K, Sehdev A, Sung MW, Hwang JJ. Phase II study of fluorouracil (FU), leucovorin (LV), and nanoliposomal irinotecan (nal-IRI) in previously treated advanced biliary tract cancer (NAPOLI-2). J Clin Oncol. 2020;38(4_suppl):TPS593. doi:10.1200/JCO.2020.38.4_suppl.TPS593
   Web of Science ®Google Scholar
• Wang-Gillam A, Li CP, Bodoky G, et al. Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial. Lancet. 2016;387(10018):545–557. doi:10.1016/S0140-6736(15)00986-1
   PubMed Web of Science ®Google Scholar
• Wainberg ZA, Melisi D, Macarulla T, et al. NALIRIFOX versus nab-paclitaxel and gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (NAPOLI 3): a randomised, open-label, phase 3 trial. Lancet. 2023;402(10409):1272–1281. doi:10.1016/S0140-6736(23)01366-1
   PubMed Web of Science ®Google Scholar
• Ide Y, Otsuka T, Shimokawa M, et al. Conversion surgery for unresectable pancreatic cancer treated with FOLFIRINOX or Gemcitabine Plus Nab-paclitaxel. Anticancer Res. 2023;43(4):1817–1826. doi:10.21873/anticanres.16335
   PubMed Web of Science ®Google Scholar
• Carrato A, Pazo-Cid R, Macarulla T, et al. Sequential nab-paclitaxel/gemcitabine followed by modified FOLFOX for first-line metastatic pancreatic cancer: the SEQUENCE trial. J Clin Oncol. 2022;40(16_suppl):4022. doi:10.1200/JCO.2022.40.16_suppl.4022
   Web of Science ®Google Scholar
• Kasi A, Iglesias JL. A phase 1/2 study to evaluate the safety, tolerability, and preliminary efficacy of GP-2250 in combination with gemcitabine for advanced or metastatic pancreatic adenocarcinoma. J Clin Oncol. 2022;40(4_suppl):TPS620. doi:10.1200/JCO.2022.40.4_suppl.TPS620
   Web of Science ®Google Scholar
• Majchrzak-Stiller B, Buchholz M, Peters I, et al. GP-2250, a novel anticancer agent, inhibits the energy metabolism, activates AMP-Kinase and impairs the NF-kB pathway in pancreatic cancer cells. J Cell Mol Med. 2023;27(14):2082–2092. doi:10.1111/jcmm.17825
   PubMed Web of Science ®Google Scholar
• Gwinn DM, Lee AG, Briones-Martin-Del-Campo M, et al. Oncogenic KRAS regulates amino acid homeostasis and asparagine biosynthesis via ATF4 and alters sensitivity to L-asparaginase. Cancer Cell. 2018;33(1):91–107.e6. doi:10.1016/j.ccell.2017.12.003
   PubMed Web of Science ®Google Scholar
• Ali U, Naveed M, Ullah A, et al. L-asparaginase as a critical component to combat Acute Lymphoblastic Leukaemia (ALL): a novel approach to target ALL. Eur J Pharmacol. 2016;771:199–210. doi:10.1016/j.ejphar.2015.12.023
   PubMed Web of Science ®Google Scholar
• Hammel P, Fabienne P, Mineur L, et al. Erythrocyte-encapsulated asparaginase (eryaspase) combined with chemotherapy in second-line treatment of advanced pancreatic cancer: an open-label, randomized Phase IIb trial. Eur J Cancer. 2020;124:91–101. doi:10.1016/j.ejca.2019.10.020
   PubMed Web of Science ®Google Scholar
• Hammel P, Feliu J, Parner V, et al. TRYbeCA-1: a randomized, phase 3 study of eryaspase in combination with chemotherapy versus chemotherapy alone as second-line treatment in patients with pancreatic adenocarcinoma (NCT03665441). Ann Oncol. 2019;30:iv26. doi:10.1093/annonc/mdz155.097
   Google Scholar
• Eser S, Schnieke A, Schneider G, Saur D. Oncogenic KRAS signalling in pancreatic cancer. Br J Cancer. 2014;111(5):817–822. doi:10.1038/bjc.2014.215
   PubMed Web of Science ®Google Scholar
• Wang X, Allen S, Blake JF, et al. Identification of MRTX1133, a noncovalent, potent, and selective KRASG12D inhibitor. J Med Chem. 2022;65(4):3123–3133. doi:10.1021/acs.jmedchem.1c01688
   PubMed Web of Science ®Google Scholar
• Strickler JH, Satake H, George TJ, et al. Sotorasib in KRAS p.G12C-mutated advanced pancreatic cancer. N Engl J Med. 2023;388(1):33–43. doi:10.1056/NEJMoa2208470
   PubMed Web of Science ®Google Scholar
• Bekaii-Saab TS, Spira AI, Yaeger R, et al. KRYSTAL-1: updated activity and safety of adagrasib (MRTX849) in patients (Pts) with unresectable or metastatic pancreatic cancer (PDAC) and other gastrointestinal (GI) tumors harboring a KRAS G12C mutation. J Clin Oncol. 2022;40(4_suppl):519. doi:10.1200/JCO.2022.40.4_suppl.519
   PubMed Web of Science ®Google Scholar
• Laskin J, Liu SV, Tolba K, et al. NRG1 fusion-driven tumors: biology, detection, and the therapeutic role of Afatinib and other ErbB-targeting agents. Ann Oncol. 2020;31(12):1693–1703. doi:10.1016/j.annonc.2020.08.2335
   PubMed Web of Science ®Google Scholar
• Aguirre AJ. Oncogenic NRG1 fusions: a new hope for targeted therapy in pancreatic cancer. Clin Cancer Res. 2019;25(15):4589–4591. doi:10.1158/1078-0432.CCR-19-1280
   PubMed Web of Science ®Google Scholar
• Fernandez-Cuesta L, Thomas RK. Molecular pathways: targeting NRG1 fusions in lung cancer. Clin Cancer Res. 2015;21(9):1989–1994. doi:10.1158/1078-0432.CCR-14-0854
   PubMed Web of Science ®Google Scholar
• Drilon A, Somwar R, Mangatt BP, et al. Response to ERBB3-directed targeted therapy in NRG1-rearranged cancers. Cancer Discov. 2018;8(6):686–695.
   PubMed Web of Science ®Google Scholar
• Rose S. MCLA-128 fights NRG1 fusion-positive cancers. Cancer Discov. 2019;9(12):1636.
   Web of Science ®Google Scholar
• Schram AM, Goto K, Kim DW, et al. Efficacy and safety of zenocutuzumab, a HER2 x HER3 bispecific antibody, across advanced NRG1 fusion (NRG1+) cancers. J Clin Oncol. 2022;40(16_suppl):105. doi:10.1200/JCO.2022.40.16_suppl.105
   PubMed Web of Science ®Google Scholar
• Kato S, Subbiah V, Marchlik E, Elkin SK, Carter JL, Kurzrock R. RET aberrations in diverse cancers: next-generation sequencing of 4871 patients. Clin Cancer Res. 2017;23(8):1988–1997. doi:10.1158/1078-0432.CCR-16-1679
   PubMed Web of Science ®Google Scholar
• Singhi AD, Ali SM, Lacy J, et al. Identification of targetable ALK rearrangements in pancreatic ductal adenocarcinoma. J Natl Compr Canc Netw. 2017;15(5):555–562. doi:10.6004/jnccn.2017.0058
   PubMed Web of Science ®Google Scholar
• Helsten T, Elkin S, Arthur E, Tomson BN, Carter J, Kurzrock R. The FGFR landscape in cancer: analysis of 4853 tumors by next-generation sequencing. Clin Cancer Res. 2016;22(1):259–267. doi:10.1158/1078-0432.CCR-14-3212
   PubMed Web of Science ®Google Scholar
• Westphalen CB, Krebs MG, Le Tourneau C, et al. Genomic context of NTRK1/2/3 fusion-positive tumours from a large real-world population. NPJ Precis Oncol. 2021;5(1):69. doi:10.1038/s41698-021-00206-y
   PubMed Web of Science ®Google Scholar
• Qin C, Yang G, Yang J, et al. Metabolism of pancreatic cancer: paving the way to better anticancer strategies. Mol Cancer. 2020;19(1):50. doi:10.1186/s12943-020-01169-7
   PubMed Web of Science ®Google Scholar
• Pająk B. Looking for the Holy Grail—drug candidates for glioblastoma multiforme chemotherapy. Biomedicines. 2022;10(5):1001. doi:10.3390/biomedicines10051001
   PubMed Web of Science ®Google Scholar
• Tataranni T, Agriesti F, Pacelli C, et al. Dichloroacetate affects mitochondrial function and stemness-associated properties in pancreatic cancer cell lines. Cells. 2019;8(5):478. doi:10.3390/cells8050478
   PubMed Web of Science ®Google Scholar
• Feuerecker B, Biechl P, Veltkamp C, Saur D, Eisenreich W. Metabolic response of pancreatic carcinoma cells under treatment with dichloroacetate. Metabolites. 2021;11(6):350. doi:10.3390/metabo11060350
   PubMed Web of Science ®Google Scholar
• Carbone D, De Franco M, Pecoraro C, et al. Structural manipulations of marine natural products inspire a new library of 3-Amino-1,2,4-triazine PDK inhibitors endowed with antitumor activity in pancreatic ductal adenocarcinoma. Mar Drugs. 2023;21(5):288. doi:10.3390/md21050288
   PubMed Web of Science ®Google Scholar
• Jiang H, Hegde S, Knolhoff BL, et al. Targeting focal adhesion kinase renders pancreatic cancers responsive to checkpoint immunotherapy. Nat Med. 2016;22(8):851–860. doi:10.1038/nm.4123
   PubMed Web of Science ®Google Scholar
• Burns C, Murphy K, Cock TA, Devlin M, Herrmann D, Timpson P. The effect of adding a selective FAK inhibitor AMP945 to FOLFIRINOX in a model of pancreatic cancer. J Clin Oncol. 2023;41(16_suppl):e15128. doi:10.1200/JCO.2023.41.16_suppl.e15128
   Web of Science ®Google Scholar
• Wang-Gillam A, Lim KH, McWilliams R, et al. Defactinib, pembrolizumab, and gemcitabine in patients with advanced treatment refractory pancreatic cancer: a Phase I dose escalation and expansion study. Clin Cancer Res. 2022;28(24):5254–5262. doi:10.1158/1078-0432.CCR-22-0308
   PubMed Web of Science ®Google Scholar
• Hingorani SR, Zheng L, Bullock AJ, et al. HALO 202: randomized Phase II Study of PEGPH20 Plus Nab-Paclitaxel/Gemcitabine versus Nab-Paclitaxel/Gemcitabine in patients with untreated, metastatic pancreatic ductal adenocarcinoma. J Clin Oncol. 2018;36(4):359–366. doi:10.1200/JCO.2017.74.9564
   PubMed Web of Science ®Google Scholar
• Ramanathan RK, McDonough SL, Philip PA, et al. Phase IB/II Randomized Study of FOLFIRINOX Plus Pegylated Recombinant Human Hyaluronidase Versus FOLFIRINOX alone in patients with metastatic pancreatic adenocarcinoma: SWOG S1313. J Clin Oncol. 2019;37(13):1062–1069. doi:10.1200/JCO.18.01295
   PubMed Web of Science ®Google Scholar
• Diaz L, Marabelle A, Kim TW, et al. Efficacy of pembrolizumab in Phase 2 KEYNOTE-164 and KEYNOTE-158 studies of microsatellite instability high cancers. Ann Oncol. 2017;28:v128–v129. doi:10.1093/annonc/mdx367.020
   PubMed Web of Science ®Google Scholar
• Geoerger B, Kang HJ, Yalon-Oren M, et al. Phase 1/2 KEYNOTE-051 study of pembrolizumab (pembro) in pediatric patients (pts) with advanced melanoma or a PD-L1+advanced, relapsed, or refractory solid tumor or lymphoma. J Clin Oncol. 2017;35(15_suppl):10525. doi:10.1200/JCO.2017.35.15_suppl.10525
   Google Scholar
• Le DT, Durham JN, Smith KN, et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science. 2017;357(6349):409–413. doi:10.1126/science.aan6733
   PubMed Web of Science ®Google Scholar
• Haas AR, Tanyi JL, O’Hara MH, et al. Phase I study of lentiviral-transduced chimeric antigen receptor-modified T cells recognizing mesothelin in advanced solid cancers. Mol Ther. 2019;27(11):1919–1929. doi:10.1016/j.ymthe.2019.07.015
   PubMed Web of Science ®Google Scholar
• Wang D, Porter CE, Lim B, et al. Ultralow-dose binary oncolytic/helper-dependent adenovirus promotes antitumor activity in preclinical and clinical studies. Sci Adv. 2023;9(13):eade6790. doi:10.1126/sciadv.ade6790
   PubMed Web of Science ®Google Scholar
• Coston T, Desai A, Babiker H, et al. Efficacy of immune checkpoint inhibition and cytotoxic chemotherapy in mismatch repair-deficient and microsatellite instability-high pancreatic cancer: Mayo Clinic experience. JCO Precis Oncol. 2023;7(7):e2200706. doi:10.1200/PO.22.00706
   PubMedGoogle Scholar
• Taïeb J, Sayah L, Heinrich K, et al. Efficacy of immune checkpoint inhibitors in microsatellite unstable/mismatch repair-deficient advanced pancreatic adenocarcinoma: an AGEO European Cohort. Eur J Cancer. 2023;188:90–97. doi:10.1016/j.ejca.2023.04.012
   PubMed Web of Science ®Google Scholar
• Yang F, He Z, Duan H, et al. Synergistic immunotherapy of glioblastoma by dual targeting of IL-6 and CD40. Nat Commun. 2021;12(1):3424. doi:10.1038/s41467-021-23832-3
   PubMed Web of Science ®Google Scholar
• Mace TA, Shakya R, Pitarresi JR, et al. IL-6 and PD-L1 antibody blockade combination therapy reduces tumour progression in murine models of pancreatic cancer. Gut. 2018;67(2):320–332. doi:10.1136/gutjnl-2016-311585
   PubMed Web of Science ®Google Scholar
• Akce M, Shaib WL, Diab M, et al. Phase Ib/II trial of siltuximab and spartalizumab in patients in metastatic pancreatic cancer. J Clin Oncol. 2022;40(4_suppl):TPS626. doi:10.1200/JCO.2022.40.4_suppl.TPS626
   Web of Science ®Google Scholar
• Frankel SR, Baeuerle PA. Targeting T cells to tumor cells using bispecific antibodies. Curr Opin Chem Biol. 2013;17(3):385–392. doi:10.1016/j.cbpa.2013.03.029
   PubMed Web of Science ®Google Scholar
• Leung RCY, Yau T, Wong DA, Luk JM, de Souza PL. Phase 1A, first-in-human study of ARB202, bispecific antibody to CDH17 and CD3, in advanced gastrointestinal malignancies expressing CDH17. JCO Glob Oncol. 2023;9(Supplement_1):25. doi:10.1200/GO.2023.9.Supplement_1.25
   Google Scholar
• Liu X, Huang Y, Yuan H, et al. Disruption of oncogenic liver-intestine cadherin (CDH17) drives apoptotic pancreatic cancer death. Cancer Lett. 2019;454:204–214. doi:10.1016/j.canlet.2019.04.022
   PubMed Web of Science ®Google Scholar
• O’Reilly EM, Wainberg ZA, Weekes CD, et al. AMPLIFY-201, a first-in-human safety and efficacy trial of adjuvant ELI-002 2P immunotherapy for patients with high-relapse risk with KRAS G12D- or G12R-mutated pancreatic and colorectal cancer. J Clin Oncol. 2023;41(16_suppl):2528.
   Web of Science ®Google Scholar
• Schmidt M, Vogler I, Derhovanessian E, et al. 88MO T-cell responses induced by an individualized neoantigen specific immune therapy in post (neo)adjuvant patients with triple negative breast cancer. Ann Oncol. 2020;31:S276. doi:10.1016/j.annonc.2020.08.209
   Web of Science ®Google Scholar
• Kopetz S, Morris VK, Alonso-Orduña V, et al. A phase 2 multicenter, open-label, randomized, controlled trial in patients with stage II/III colorectal cancer who are ctDNA positive following resection to compare efficacy of autogene cevumeran versus watchful waiting. J Clin Oncol. 2022;40(16_suppl):TPS3641. doi:10.1200/JCO.2022.40.16_suppl.TPS3641
   Google Scholar
• Rojas LA, Sethna Z, Soares KC, et al. Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer. Nature. 2023;618(7963):144–150. doi:10.1038/s41586-023-06063-y
   PubMed Web of Science ®Google Scholar
• Argani P, Iacobuzio-Donahue C, Ryu B, et al. Mesothelin is overexpressed in the vast majority of ductal adenocarcinomas of the pancreas: identification of a new pancreatic cancer marker by serial analysis of gene expression (SAGE). Clin Cancer Res. 2001;7(12):3862–3868.
   PubMed Web of Science ®Google Scholar
• Hassan R, Thomas A, Alewine C, Le DT, Jaffee EM, Pastan I. Mesothelin immunotherapy for cancer: ready for prime time? J Clin Oncol. 2016;34(34):4171–4179. doi:10.1200/JCO.2016.68.3672
   PubMed Web of Science ®Google Scholar
• Alewine C, Ahmad M, Peer CJ, et al. Phase I/II study of the mesothelin-targeted immunotoxin LMB-100 with Nab-Paclitaxel for patients with advanced pancreatic adenocarcinoma. Clin Cancer Res. 2020;26(4):828–836. doi:10.1158/1078-0432.CCR-19-2586
   PubMed Web of Science ®Google Scholar
• Simon N, Antignani A, Hewitt SM, Gadina M, Alewine C, FitzGerald D. Tofacitinib enhances delivery of antibody-based therapeutics to tumor cells through modulation of inflammatory cells. JCI Insight. 2019;4(5). doi:10.1172/jci.insight.123281
   Web of Science ®Google Scholar
• Amini L, Silbert SK, Maude SL, et al. Preparing for CAR T cell therapy: patient selection, bridging therapies and lymphodepletion. Nat Rev Clin Oncol. 2022;19(5):342–355. doi:10.1038/s41571-022-00607-3
   PubMed Web of Science ®Google Scholar
• Beatty GL, O’Hara MH, Lacey SF, et al. Activity of mesothelin-specific chimeric antigen receptor T cells against pancreatic carcinoma metastases in a Phase 1 trial. Gastroenterology. 2018;155(1):29–32. doi:10.1053/j.gastro.2018.03.029
   PubMed Web of Science ®Google Scholar
• Liu Y, Guo Y, Wu Z, et al. Anti-EGFR chimeric antigen receptor-modified T cells in metastatic pancreatic carcinoma: a phase I clinical trial. Cytotherapy. 2020;22(10):573–580. doi:10.1016/j.jcyt.2020.04.088
   PubMed Web of Science ®Google Scholar
• Feng K, Liu Y, Guo Y, et al. Phase I study of chimeric antigen receptor modified T cells in treating HER2-positive advanced biliary tract cancers and pancreatic cancers. Protein Cell. 2018;9(10):838–847. doi:10.1007/s13238-017-0440-4
   PubMed Web of Science ®Google Scholar
• Bazan-Peregrino M, Garcia-Carbonero R, Laquente B, et al. VCN-01 disrupts pancreatic cancer stroma and exerts antitumor effects. J Immunother Cancer. 2021;9(11):e003254. doi:10.1136/jitc-2021-003254
   PubMed Web of Science ®Google Scholar
• Garcia-Carbonero R, Bazan-Peregrino M, Gil-Martín M, et al. Phase I, multicenter, open-label study of intravenous VCN-01 oncolytic adenovirus with or without nab-paclitaxel plus gemcitabine in patients with advanced solid tumors. J Immunother Cancer. 2022;10(3):e003255. doi:10.1136/jitc-2021-003255
   PubMed Web of Science ®Google Scholar